OLIVA, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 1946
EU - Europa 1588
AS - Asia 798
SA - Sud America 50
OC - Oceania 36
AF - Africa 13
Totale 4431
Nazione #
US - Stati Uniti d'America 1856
IT - Italia 768
CN - Cina 405
SE - Svezia 150
JP - Giappone 125
DE - Germania 115
IE - Irlanda 113
GB - Regno Unito 99
KR - Corea 80
CA - Canada 67
FR - Francia 58
IN - India 58
VN - Vietnam 49
NL - Olanda 39
AU - Australia 30
BE - Belgio 30
UA - Ucraina 30
ES - Italia 29
FI - Finlandia 27
BR - Brasile 25
CH - Svizzera 24
MX - Messico 20
TR - Turchia 20
PL - Polonia 18
GR - Grecia 14
CO - Colombia 13
AT - Austria 12
PT - Portogallo 12
RU - Federazione Russa 12
DK - Danimarca 11
SG - Singapore 10
TH - Thailandia 9
HU - Ungheria 8
PK - Pakistan 8
CL - Cile 7
ID - Indonesia 6
IR - Iran 6
NZ - Nuova Zelanda 6
TW - Taiwan 6
AR - Argentina 4
EG - Egitto 4
HK - Hong Kong 4
HR - Croazia 4
IL - Israele 4
RO - Romania 4
SN - Senegal 4
DZ - Algeria 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
CZ - Repubblica Ceca 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
CU - Cuba 1
EC - Ecuador 1
GT - Guatemala 1
KZ - Kazakistan 1
MN - Mongolia 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
Totale 4431
Città #
Florence 239
Chandler 171
Fairfield 133
Ashburn 113
Dublin 110
Beijing 108
Torino 104
Wilmington 87
Houston 84
Woodbridge 82
Redwood City 75
Nyköping 72
Duncan 70
Seattle 59
Cambridge 52
Turin 47
Tokyo 44
Dearborn 40
Ottawa 40
Ann Arbor 38
Shanghai 34
Medford 33
Hangzhou 30
Raritan 28
Princeton 27
Dong Ket 25
San Francesco 24
Guangzhou 23
Villeurbanne 22
Jacksonville 21
Nanjing 17
Brussels 16
London 16
Campi Bisenzio 15
Changchun 15
Loma Linda 14
Wuhan 14
Rochester 13
Rome 13
Seoul 13
Boston 12
Fremont 12
Milan 12
Nanchang 12
New York 12
Pisa 12
Vienna 11
Baotou 10
Chengdu 10
Xian 10
Padova 9
Changsha 8
San Diego 8
San Mateo 8
São Paulo 8
Udine 8
Zhengzhou 8
Hebei 7
Hyderabad 7
Islamabad 7
Medellín 7
Ontario 7
Santiago 7
Sydney 7
Budapest 6
Hefei 6
Taipei 6
Tianjin 6
Warsaw 6
Barcelona 5
Chennai 5
Chicago 5
Detroit 5
Forcoli 5
Fuzhou 5
Oxford 5
Paris 5
Phoenix 5
Singapore 5
Tacoma 5
Venaria 5
Watertown 5
Altfraunhofen 4
Bangalore 4
Bern 4
Bologna 4
Brisbane 4
Den Haag 4
Durham 4
Falls Church 4
Flushing 4
Geelong 4
Gîza 4
Helsinki 4
Jakarta 4
Madrid 4
Margherita Di Savoia 4
Moscow 4
Philadelphia 4
Pittsburgh 4
Totale 2567
Nome #
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1433
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 725
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 226
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 203
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 197
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 171
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 155
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 150
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 131
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 115
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 114
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 97
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma 96
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents 84
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 74
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 68
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 67
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 64
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives 61
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 51
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 50
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set 49
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 45
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 43
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time? 41
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 38
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials 24
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 15
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 8
Totale 4595
Categoria #
all - tutte 7110
article - articoli 0
book - libri 0
conference - conferenze 237
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7347


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201832 0000 00 00 00032
2018/2019541 54485357 5426 2639 45435640
2019/2020768 43333788 5763 4847 129918547
2020/2021784 51426147 9965 7379 57545898
2021/2022856 556137102 5643 3957 3975149143
2022/2023787 531075792 56138 5157 8133620
Totale 4595